Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
5.Shiba-Ishii A, Johnson TW, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022. 3(6): 710-722. ...
Clinical Lung CancerSahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wa n nesson L, A ntonel l i P, Ba l za r i n i P, Sessa F, Mazzucchelli L, et al: EGFR and KRAS mutations in ALK‑positive lung adenocarcinomas: Biological and ...
在约50-60%对第二代ALK-TKI耐药的患者中,ALK基因激酶结构域出现的继发突变(Secondary Mutation)是导致耐药的原因,涉及的机制包括直接阻碍ALK-TKI与位点结合,导致蛋白激酶构象改变和/或影响ATP结合等。 与第一代/第二代EGFR-TKI的耐药继发突变大多为T790M突变不同,ALK继发突变的类型很多,目前主要的已知突变有L1196M...
[1]Solomon B J, Bauer T M, Mok T S K, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from t...
9、Solomon B J, Kim D W, Wu Y L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer[J]. Journal of Clinical Oncology, 2018, 36(22): 2251-2258. ...
[1]Solomon B J, Bauer T M, Mok T S K, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. The Lancet Respiratory ...
[4]Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.[5]Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer.[6]First-line ceritinib versus platinum-based chemotherapy in ...
1.Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways 2.Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology | JAMA Network ...
[3]Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. ...